EXECUTIVE SUMMARY:
This final audit report prepared by KPMG Peat Marwick (KPMG), independent public accountants, under contract with the Office of Inspector General indicates opportunity for improving financial management at the Food and Drug Administration (FDA). The Chief Financial Officers Act requires that the audit report be prepared in accordance with Government Auditing Standards and the Office of Management and Budget's Bulletin 93-06, Audit Requirements for Federal Financial Statements. The KPMG's auditors expressed an unqualified opinion on FDA's Revolving Fund for Certification and Other Services' (Fund) financial statements but found problems with internal controls and compliance with laws and regulations in the areas of input and processing controls, overhead allocation, and proprietary and budgetary account balancing. They also found that while some prior year problems were resolved, other problems found in the previous year's audit have not been fully resolved.